First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: MSC2363318A
DRUG: MSC2363318A plus Trastuzumab
DRUG: MSC2363318A plus Tamoxifen

Sponsor

EMD Serono